Management of diabetic retinopathy

The effect of anti-inflammatory and anti-neovascularization TIPE2 on diabetic retinopathy

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900024358

Enrollment

Unknown

Registered

2019-07-06

Start date

2019-07-06

Completion date

Unknown

Last updated

2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy

Interventions

diabetic retinopathy group:N/A

non-diabetes group:N/A

Eligibility

Sex/Gender

All

Age

7 Years to 100 Years

Inclusion criteria

Inclusion criteria: DR patient receiving ocualr surgery; Non-diabetic patient receiving ocular surgery.

Exclusion criteria

Exclusion criteria: Other systemic disease.

Design outcomes

Primary

Measure	Time frame
TIPE2;VEGF;blood glucose;	—

Countries

China

Contacts

Public ContactQin Xuejiao

Qilu Hospital, Shandong University

qinxuejiao@hotmail.com+86 18560087100

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026